Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Primary listing
Employees
97
Headquarters
Website
TBPH Metrics
BasicAdvanced
$687M
53.31
$0.26
0.01
-
Price and volume
Market cap
$687M
Beta
0.01
52-week high
$14.55
52-week low
$7.88
Average daily volume
486K
Financial strength
Current ratio
6.705
Quick ratio
6.603
Long term debt to equity
15.816
Total debt to equity
15.816
Interest coverage (TTM)
-13.82%
Profitability
EBITDA (TTM)
-34.311
Gross margin (TTM)
47.33%
Net profit margin (TTM)
16.88%
Operating margin (TTM)
-46.16%
Effective tax rate (TTM)
67.49%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
-5.65%
Return on equity (TTM)
6.23%
Valuation
Price to earnings (TTM)
53.311
Price to revenue (TTM)
8.756
Price to book
3.06
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
2.762
Free cash flow yield (TTM)
36.21%
Free cash flow per share (TTM)
4.939
Growth
Revenue change (TTM)
24.49%
Earnings per share change (TTM)
-127.83%
3-year revenue growth (CAGR)
13.80%
10-year revenue growth (CAGR)
8.14%
3-year earnings per share growth (CAGR)
-42.70%
10-year earnings per share growth (CAGR)
-27.57%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
Bulls say / Bears say
YUPELRI net sales rose 22% year-over-year to $66.3 million in Q2 2025, driven by improved net pricing and a 31% increase in hospital channel dosing, underscoring strong commercial performance. (PRNewswire)
Theravance monetized its remaining TRELEGY Ellipta royalty interest through a $225 million cash sale to GSK, strengthening its balance sheet to $338.8 million in cash and eliminating debt. (PRNewswire)
Cash, cash equivalents, and marketable securities totaled $338.8 million as of June 30, 2025, providing significant runway to fund operations and advance the pipeline. (PRNewswire)
Despite reporting net income of $54.8 million in Q2 2025, Theravance’s core non-GAAP operations still posted a $4.2 million loss, highlighting dependence on one-time royalty monetization for profitability. (PRNewswire)
Topline data from the pivotal Phase 3 CYPRESS study of ampreloxetine are not expected until Q1 2026, leaving an extended catalyst gap and exposing the equity to clinical trial risk. (PRNewswire)
Total Q2 2025 revenue was $26.2 million, reflecting modest commercial scale and continued reliance on partner-derived milestones and collaboration revenues. (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $687M as of September 14, 2025.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 53.31 as of September 14, 2025.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.